Collegium Pharmaceutical (COLL) Projected to Post Earnings on Thursday

Collegium Pharmaceutical (NASDAQ:COLL) will likely be releasing its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of $2.20 per share for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:00 AM ET.

Collegium Pharmaceutical Price Performance

Collegium Pharmaceutical stock opened at $45.29 on Thursday. The company has a market capitalization of $1.43 billion, a price-to-earnings ratio of 28.13 and a beta of 0.64. The company has a current ratio of 1.36, a quick ratio of 1.27 and a debt-to-equity ratio of 2.71. Collegium Pharmaceutical has a 12 month low of $23.23 and a 12 month high of $50.79. The stock’s 50 day moving average is $47.10 and its 200-day moving average is $41.52.

Insider Buying and Selling

In other Collegium Pharmaceutical news, Director Rita J. Balice-Gordon sold 3,650 shares of the business’s stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $47.03, for a total transaction of $171,659.50. Following the completion of the transaction, the director directly owned 52,629 shares in the company, valued at $2,475,141.87. The trade was a 6.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Scott Dreyer sold 17,600 shares of the company’s stock in a transaction on Monday, December 8th. The stock was sold at an average price of $48.17, for a total value of $847,792.00. Following the sale, the executive vice president owned 103,613 shares of the company’s stock, valued at $4,991,038.21. The trade was a 14.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 2.51% of the company’s stock.

Institutional Trading of Collegium Pharmaceutical

Institutional investors and hedge funds have recently modified their holdings of the business. Vident Advisory LLC raised its stake in Collegium Pharmaceutical by 1.9% during the third quarter. Vident Advisory LLC now owns 15,466 shares of the specialty pharmaceutical company’s stock worth $541,000 after acquiring an additional 281 shares in the last quarter. Quadrant Capital Group LLC increased its position in Collegium Pharmaceutical by 4.2% during the 4th quarter. Quadrant Capital Group LLC now owns 6,996 shares of the specialty pharmaceutical company’s stock worth $324,000 after purchasing an additional 282 shares in the last quarter. Atom Investors LP increased its position in Collegium Pharmaceutical by 5.0% during the 4th quarter. Atom Investors LP now owns 6,124 shares of the specialty pharmaceutical company’s stock worth $284,000 after purchasing an additional 294 shares in the last quarter. Group One Trading LLC bought a new position in Collegium Pharmaceutical in the 4th quarter valued at approximately $28,000. Finally, Sei Investments Co. boosted its position in Collegium Pharmaceutical by 5.5% in the second quarter. Sei Investments Co. now owns 11,436 shares of the specialty pharmaceutical company’s stock valued at $338,000 after buying an additional 600 shares in the last quarter.

Analysts Set New Price Targets

COLL has been the topic of several recent research reports. Barclays lowered their price objective on Collegium Pharmaceutical from $58.00 to $56.00 and set an “overweight” rating on the stock in a research report on Friday, January 9th. Wall Street Zen raised shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Zacks Research downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 6th. Truist Financial set a $58.00 target price on shares of Collegium Pharmaceutical in a research report on Tuesday, February 10th. Finally, Weiss Ratings reiterated a “buy (b-)” rating on shares of Collegium Pharmaceutical in a research report on Monday, December 29th. Five equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $53.40.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.